Department of Biomedicine of Developing Age, University of Bari, 70124 Bari, Italy.
J Endocrinol Invest. 2010 Mar;33(3):135-9. doi: 10.1007/BF03346571. Epub 2009 Jul 28.
Scanty data are available about the thyroid function in childhood acute lymphoblastic leukemia (ALL) off-therapy patients treated only with chemotherapy. We aimed to assess the prevalence of thyroid autoimmunity and thyroid dysfunction in such patients.
Case-control cross-sectional study.
Eighty-four patients diagnosed with ALL and treated only with chemotherapy. Mean age at diagnosis 5.9+/-3.6 yr, at recruitment 12.1+/-4.3 yr. The treatment had been stopped 4.3+/-3.2 yr before recruitment. A control group of 60 subjects was recruited. Free T4, TSH, anti-thyroperoxidase, and anti-thyroglobulin antibodies were measured.
Anti-thyroglobulin and anti-thyroperoxidase antibodies were negative in all patients. TSH was increased in 7 patients (8.3%) and 3 controls (5.0%). Free T4 was within the normal limits in all patients and controls.Mean TSH and free T4 levels did not statistically differ between controls and ALL offtherapy patients. TSH was negatively correlated with the age at the diagnosis (p=0.01) and the age at the end of therapy (p=0.008). Anti-thyroglobulin and/or anti-thyroperoxidase antibodies were detected in 3 controls (5%; vs study group: p=0.038), 1 of them with increased TSH.
Some patients present hyperthyrotropinemia, without anti-thyroid antibodies, with a prevalence comparable to the control group. The thyroid gland seems more prone to be damaged by chemotherapy at a younger age. We think that a thyroid follow- up in ALL off-therapy patients may be advisable and should be differentiated on the basis of the age at the end of treatment, with more frequent tests for younger patients.
仅有化疗治疗的儿童急性淋巴细胞白血病(ALL)停药后患者甲状腺功能的数据有限。我们旨在评估此类患者甲状腺自身免疫和甲状腺功能障碍的发生率。
病例对照横断面研究。
84 例诊断为 ALL 且仅接受化疗的患者。诊断时的平均年龄为 5.9+/-3.6 岁,招募时为 12.1+/-4.3 岁。招募前治疗已停止 4.3+/-3.2 年。招募了 60 名对照组受试者。测量游离 T4、TSH、抗甲状腺过氧化物酶和抗甲状腺球蛋白抗体。
所有患者的抗甲状腺球蛋白和抗甲状腺过氧化物酶抗体均为阴性。7 名患者(8.3%)和 3 名对照者(5.0%)TSH 升高。所有患者和对照组的游离 T4 均在正常范围内。对照组和 ALL 停药患者的 TSH 和游离 T4 水平无统计学差异。TSH 与诊断时年龄(p=0.01)和治疗结束时年龄(p=0.008)呈负相关。3 名对照者(5%;与研究组相比:p=0.038)检测到抗甲状腺球蛋白和/或抗甲状腺过氧化物酶抗体,其中 1 名 TSH 升高。
一些患者表现为促甲状腺素升高,无甲状腺抗体,其患病率与对照组相当。甲状腺似乎更容易在年轻时因化疗而受损。我们认为 ALL 停药后患者可能需要进行甲状腺随访,应根据治疗结束时的年龄进行区分,对年龄较小的患者进行更频繁的检查。